GB918929A — Improvements in or relating to process for the manufacture of therapeutic useful preparations of iron
Assigned to Vifor International AG · Expires 1963-02-20 · 63y expired
What this patent protects
A therapeutically useful ferric hydroxide-partially depolymerized dextrin complex is obtained by mixing an aqueous solution of a water soluble dextrin fraction having an average intrinsic viscosity at 25 DEG C. of from 0,025 to 0,075 with an aqueous solution containing ferrous or…
USPTO Abstract
A therapeutically useful ferric hydroxide-partially depolymerized dextrin complex is obtained by mixing an aqueous solution of a water soluble dextrin fraction having an average intrinsic viscosity at 25 DEG C. of from 0,025 to 0,075 with an aqueous solution containing ferrous or ferric ions or a suspension of ferrous or ferric hydroxide and an excess of alkali, heating the reaction mixture to form the ferrous or ferric complex and in the former case oxidizing to give the ferric complex. The initial dextrin is preferably obtained by roasting starch in the presence of an acid. In a typical example (No. 2) dextrin is heated in water at 75 DEG C. and firstly ferric hydroxide solution and then caustic soda solution added slowly. After cooling the pH is adjusted to 6,2 and ethyl alcohol added and the solution rendered isotonic by the addition of sodium chloride and then filled into ampoules. Phenol may be added as a preservative. Specification 748,024 is referred to.ALSO:A therapeutically useful ferric-hydroxide-partially depolymerized dextrin complex is obtained by mixing an aqueous solution of a water soluble dextrin fraction having an average intrinsic viscosity at 25 DEG C. of from 0.025 to 0.075 with an aqueous solution containing ferrous or ferric ions or a suspension of ferrous or ferric hydroxide and an excess of alkali, heating the reaction mixture to form the ferrous or ferric complex and in the former case oxidizing to give the ferric complex. The complex may be prepared from dextrin obtained by roasting starch with acid as described in Group IV (a). It may be rendered isotonic with sodium chloride and filled into ampoules with 0.5% of phenol as a preservative. Specification 748,024 is referred to.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.